Summary

Edoxaban was noninferior to warfarin for prevention of recurrent venous thromboembolism (VTE) in patients with acute VTE who were initially treated with heparin. This article presents data from the Comparative Investigation of Edoxaban Tosylate (DU176b) Versus Warfarin in the Treatment of Symptomatic Deep-Vein Clots and/or Lung Blood Clots trial [Edoxaban Hokusai-VTE Study; Büller HR et al. N Engl J Med 2013].